In addition to its correlation with amyloid pathology, plasma GFAP levels also gradually increase with the severity of cognitive impairment across the Alzheimer’s disease continuum, as reported by Chatterjee et al.20 Their observations were based on the Australian Imaging, Biomarker and Lifestyle longitudinal cohort (AIBL, Australia) which included 181 individuals, with GFAP being quantified using the Quanterix Simoa Neurology-4-Plex Assay. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.